RT Journal Article
SR Electronic
T1 Shared genetics between breast cancer and its predisposing diseases identify novel breast cancer treatment candidates
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.14.24307374
DO 10.1101/2024.05.14.24307374
A1 Lalagkas, Panagiotis N.
A1 Melamed, Rachel D.
YR 2024
UL http://medrxiv.org/content/early/2024/05/15/2024.05.14.24307374.abstract
AB Breast cancer is a major public health issue. Current treatment options, while effective, have severe side effects. FDA-approved drugs have known safety and pharmacological profiles and some, such as metformin, have been tested in clinical trials for repurposing for breast cancer. However, clinical trials are slow and expensive, which creates the need for innovative approaches to accelerate drug repurposing for breast cancer. We have previously shown that genes associated with Mendelian diseases that predispose patients to certain cancers are enriched for successful drug targets, due to their pleiotropic effects. Here, we extend our approach to exploit clinical associations between breast cancer and its predisposing diseases for drug repurposing. We hypothesize that pleiotropic genes shared between breast cancer and its predisposing diseases can help us discover new uses for drugs currently approved only for the predisposing diseases. To test our hypothesis, we compile a list of six traits known to increase breast cancer risk (predisposing diseases). Using GWAS summary statistics and local genetic correlation analysis, we find 84 genomic loci harboring mutations with positively correlated effects between breast cancer and each predisposing disease. These loci contain 194 protein-coding genes (shared genes). Using a network biology approach and canonical pathways, for each disease pair, we connect drugs already indicated for the predisposing disease to its shared biology with breast cancer and identify drug repurposing candidates for breast cancer. Finally, we show that our list of candidate drugs is enriched for currently investigated and indicated drugs for breast cancer (OR=9.28, p=7.99e-03). Our findings suggest a novel way to accelerate drug repurposing for complex diseases by leveraging shared genetics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementR35 GM151001-02Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All source data were publicly available at GWAS catalog.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data are all publicly available at GWAS catalog.